|
Collaboration Agreement - Additional Information (Detail) (USD $)
|
0 Months Ended | 3 Months Ended | 9 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended | 1 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jul. 02, 2014
|
Sep. 30, 2014
|
Sep. 30, 2013
|
Sep. 30, 2014
|
Sep. 30, 2013
|
Dec. 31, 2013
|
Sep. 30, 2014
Isis Pharmaceuticals Inc. and University of British Columbia [Member]
|
Dec. 31, 2009
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2014
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
|
Sep. 30, 2014
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
Minimum [Member]
|
Sep. 30, 2014
Collaboration arrangement [Member]
Teva Pharmaceutical Industries Ltd. [Member]
Maximum [Member]
|
Dec. 31, 2009
Collaboration arrangement [Member]
Isis Pharmaceuticals Inc. [Member]
|
Sep. 30, 2014
Collaboration arrangement [Member]
Isis Pharmaceuticals Inc. [Member]
|
Dec. 31, 2009
Collaboration arrangement [Member]
Isis Pharmaceuticals Inc. and University of British Columbia [Member]
|
|
| Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ||||||||||||||
| Collaboration agreement aggregate amount | $ 50,000,000 | |||||||||||||
| Maximum amount receivable | 370,000,000 | |||||||||||||
| Equity investment | 24,000,000 | 10,000,000 | ||||||||||||
| Royalties at percentage rates ranging | Mid-teens to mid-twenties on net sales | |||||||||||||
| Share premium | 20.00% | |||||||||||||
| Common shares, purchase price | $ 37.38 | |||||||||||||
| Common shares purchased | 267,531 | |||||||||||||
| Average premium period | 30 days | |||||||||||||
| Research and development | 9,586,000 | 18,004,000 | 36,372,000 | 42,122,000 | 10,000,000 | 300,000 | ||||||||
| Percentage of milestone payments required to be paid to third party | 31.00% | |||||||||||||
| Percentage of net sales required to be paid as royalty to third party | 4.88% | 8.00% | ||||||||||||
| Direct and indirect costs incurred | 30,000,000 | |||||||||||||
| Required period of notice for termination of collaboration agreement | 3 months | 6 months | ||||||||||||
| Expiration of royalties | 10 years | |||||||||||||
| Period of authorization change | 90 days | |||||||||||||
| Receivable for unbilled expense reimbursements | 4,827,000 | 4,827,000 | 8,657,000 | |||||||||||
| Milestone payment due | 20,000,000 | 20,000,000 | ||||||||||||
| Period of milestone payment | 21 days | 21 days | ||||||||||||
| Reserve for contingency of non payment of non-royalty milestone amount | 20,000,000 | 20,000,000 | ||||||||||||
| Milestone payment made | 10,000,000 | 10,000,000 | ||||||||||||
| Balance amount of milestone payment | 10,000,000 | 10,000,000 | ||||||||||||
| Balance in advanced reimbursement of development activities | $ 30,000,000 | |||||||||||||